Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Keep me logged in Forgot your password?

Please wait...

Please wait...

Business Briefs: Merck and Forest Labs

May 23, 2013

Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement.
 

Business briefs: Pfizer, Novartis, Boehringer Ingelheim, Elsevier

May 22, 2013

Pfizer seeks full Zoetis split, Novartis gets another NICE Lucentis indication, BI tussles with the FDA and Elsevier names a Cleveland Clinic doc EIC
 

Business Briefs: inVentiv; Mylan; Royalty Pharma; Pfizer; Edelman

May 21, 2013

inVentiv adds new comms exec; Julie Bowen teams up with Mylan for allergy emergencies; Royalty raises the bid on Elan; Pfizer nixes non-Hodgkin's lymphoma drug in trials.
 

Business briefs: Actavis, Bayer, Oramed, Elan

May 20, 2013

Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M
 

Business briefs: Pfizer, BMS, CMS, Sanofi

May 16, 2013

Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor.
 

Business briefs: Bayer, FDA, Ranbaxy

May 15, 2013

Bayer's prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations
 

Business briefs: Angelina Jolie, adherence, Sanofi, Teva, AbbVie

May 14, 2013

Jolie takes on cancer awareness role, researchers identify another adherence gap, Sanofi gets slapped for scare tactics, Teva may compete for Adcock, AbbVie R&D chief leaves
 

Business briefs: Eli Lilly, Millennium/Takeda, Elan

May 13, 2013

Eli Lilly nixes one trial and fails another; Millennium is folded into Takeda, Dunsire retires; Elan pays for Theravance royalties in attempt to avoid takeover.
 

Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity

May 09, 2013

HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.
 

Business briefs: Arena, Takeda, Teva, Cubist

May 08, 2013

Arena gets closer to the market place, Takeda scoops up privately held Inviragen, Plan B court decision is coming and Cubist antibotic lands breakthrough therapy status.
 

Business briefs: Baxter; Eli Lilly; CDHPs and Statins

May 07, 2013

Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV.
 

Business briefs: Pfizer and CVS; the EMA; Digitas Health New York

May 06, 2013

Pfizer's online Viagra deal with CVS; reorg at the EMA; Mills moves up at Digitas
 

Business briefs: Sanofi, Allergan, Otsuka, Genmab, NIH, Novartis, DOJ

May 02, 2013

Lantus cushions Sanofi's quarterly sales; Allergan holds back on Eylea competitor; FDA limits use of Otsuka drug; Genmab lands Breakthrough label; NIH finds a link among cancers; and Novartis offers lunch with a side of medical information; DOJ appeals Plan-B Ruling.
 

Business Briefs: Teva; Vertex; CSL Behring; Boehringer; Mylan; Amgen

May 01, 2013

FDA lowers Teva's Plan B age limit to 15; CSL Behring's anticoagulant gets approval; Pradaxa gets slapped with black box for stroke risks; Mylan recruits former FDA deputy comissioner; Amgen's Neulasta and Neupogen drugs could save you in a nuclear apocalypse.
 

Business Briefs: Manhattan Research, KPMG, Scioderm and GSK

April 30, 2013

Health-seeking consumers continue social-media push; Scioderm scores FDA's "Breakthrough" designation for bullosa agent; and GSK files NDA for airway treatment.
 

Business briefs: Merck and Pfizer; Valeant and Actavis; Bayer; Gilead

April 29, 2013

Merck and Pfizer partner up for an SGLT2 for diabetes; Bayer acquires contraceptive maker; Valeant and Actavis merger negotiations are put on hold; Gilead's HIV combo drug receives regulator setback.
 

Business Briefs: Docs question Gleevec price, Sanofi pill may delay MS onset

April 25, 2013

Doctors call out Novartis on drug prices; Aubagio shows strong top-line data in trials; and overseas docs increasingly turn to digital.
 

Business Briefs: Merck, CMS and Sucampo

April 24, 2013

Merck's experimental skin cancer drug gets breakthrough status; Tavenner's nod hits a roadblock; study shows biotechs aren't doing enough to please payers; and Sucampo's Amitiza gains a new indication.
 

Business briefs: Roche, Doximity and Bayer

April 23, 2013

Roche is shuttering a division and eliminating 170 jobs; Doximity has added another client; a cautiously-worded study indicates antidepressants may be linked to autism; and NICE has endorsed a new use for Bayer's Xarelto.
 

Business Briefs: GSK, Astellas, Vertex and Orexigen

April 22, 2013

GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment.
 

Business Briefs: AstraZeneca, Amgen, BMS and Merck

April 18, 2013

AstraZeneca cuts a deal with OCB to test unnamed cancer drug; an Enbrel biosimilar launches in India; BMS and Santaris seal an mRNA tech deal; Merck expands its China presence; Alzheimer's advocacy group parents a spin-off.
 

Business Briefs: Amgen, Allergan, Eli Lilly, DePuy

April 17, 2013

Amgen settles with DOJ over questionable Aranesp marketing; FDA denies approval for Allergan's inhalable migraine drug; Lilly posts promising top-line data of new experimental diabetes treatment; J&J wins second hip trial
 
 

Business briefs: GlaxoSmithKline, Adverse Event reporting, Elan

April 15, 2013

GSK's Avandia woes continue, study finds a new way to identify adverse events, and Royalty ups its bid for Elan.
 

Business briefs: Reps mum on adverse events; FCC's new mHealth director; med schools tighten speaking limits

April 11, 2013

A study finds sales reps find time to talk benefits, but not risks, even when touting black-box drugs; FCC has named its new mHealth director; pharma scaled back its food budgets last year; and AMSA says 18 med schools now ban faculty from speakers bureau participation
 

Business briefs: PwC, Novartis, iDoc24, FDA

April 10, 2013

PricewaterhouseCoopers says consumers are talking healthcare, but not about the good stuff; Novartis shuffles 120 Texas jobs; 73% of STD app queries came from men last month; FDA is keeping very busy; and OgilvyCommonhealth hires a consumer head
 

Business briefs: Roche, Vital Art and Science, Gilead, Sanofi

April 09, 2013

Roche and Isis pair up for Huntingtons, Vital's prescription vision app gets approved, FDA approval revives maligned morning sickness drug, Gilead sends hep C therapy to regulators and Sanofi's emerging market exposure grabs attention.
 

Business briefs: BMS, Sanofi, UK Sunshine

April 08, 2013

BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year.
 

Business briefs: Walgreens; Pfizer; Roche

April 04, 2013

Walgreens retail clinics expand diagnostic services, Pfizer says OTC is staying put, Roche-BMS melanoma drug mix runs into PHI troubles.
 

Business briefs: Bayer, AZ, Pfizer, Saatchi & Saatchi Wellness

April 03, 2013

Bayer gets ex-Pfizer comms exec; AZ acquires early-stage HDL-raising cardiovascular therapy; Pfizer inks biotech deal for access to nanoparticle delivery tech; Saatchi names digital strategy chief
 

Business briefs: AstraZeneca, Everyday Health, J&J

April 02, 2013

AstraZeneca loses in patent court and Pulmicort goes generic, Barbara Ryan joins FTI, Everyday Health and Mayo Clinic expand their advertising alliance, analyst says Ivokana side effect could limit sales
 

Business briefs: Chandler Chicco, Pfizer, FDA, Dainippon, CDC

April 01, 2013

Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses.
 

Business briefs: Lundbeck and Otsuka; Omnicom; Vivus

March 28, 2013

Otsuka-Lundbeck CNS alliance extended to Alzheimer's drug; longtime DAS chief Tom Harrison steps down to chairman emeritus role
 

Business briefs: United Concordia, FDA

March 27, 2013

United Concordia finds a way to slash healthcare costs for $4,000 a year, and FDA goes on tour to promote tighter compounding oversight
 

Business Briefs: Roche, Sanofi, J&J

March 26, 2013

NICE pans Avastin for ovarian cancer (again), Sanofi wants data innovators
 

Business briefs: Shire, AthenaHealth, GSK, Novartis

March 25, 2013

Shire expands its pipeline yet again, AthenaHealth stretches its HCP-patient reach, FDA delays GSK's bird-flu vaccine, Novartis wins approval for cystic fibrosis inhaler
 

Business briefs Merck/Cerecor, Alcon, Eli Lilly

March 21, 2013

Merck sells rights for possible Parkinson's pathway to Cerecor; Alcon launches eye and ear care adherence site; Americans draw a blank on personalized medicine, Lilly finds
 

Business briefs: Biogen Idec; Novo Nordisk and Merrion; Pfizer; FDA; inVentiv Health

March 20, 2013

Biogen's MS oral hopeful gets extra patent life; Novo's novel oral insulin passes Phase I; Pfizer gets clinical research equivalent of Good Housekeeping stamp of approval; FDA's acting generics chief; InVentiv buys stake in an electronic clinical trial company
 

Business Briefs: Novo, FDA, Biologics

March 19, 2013

Novo's weight-loss news fails to lift investor mood; GAO wants FDA to do more biologics topped 2012 sales.
 

Business briefs: HRT, HPV, Novo Nordisk

March 18, 2013

Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results
 

Business briefs: FDA wants to relax Alzheimer's approvals rules, generics office head quits

March 14, 2013

FDA intends to loosen the rules for approving new Alzheimer's disease treatments, the agency said in a proposal that ran in the New England Journal of Medicine.
 

Business briefs: Teva; CDC

March 13, 2013

Teva and Clay Walker urge MS patients to stick to their treatment regimens, while Meryl Streep and the CDC seek to get people screened for colorectal cancer.
 

Business briefs: Merck, Shire

March 12, 2013

Merck's Vytorin trial rolls on, Shire expands into neonatology
 

Business briefs: LifeScan, Havas Health

March 11, 2013

LifeScan's new glucose monitor gets an FDA green light; Havas Health merges two London shops and refreshes H4B branding
 

Business briefs: Lundbeck, FDA, Tower Watson and National Business Group Study, Merck

March 07, 2013

Lundbeck and Otsuka deepen their Abilify co-promotion partnership; study finds FDA clinical trial rule isn't sticking; another study confirms that employees are paying more for health insurance as employers pay less; Merck appoints new R&D chief
 

Business briefs: Pfizer, physicians and ACOs

March 06, 2013

Celebrex gets a life extension; nearly half of physicians can't define an ACO
 

Business briefs: Gilead, Xarelto

March 05, 2013

Gilead combo drug clears HCV; FDA denies Xarelto expanded indication for a second time
 

Business briefs: Pharma's ad spend, Baby sheds HIV status

March 04, 2013

Pharma pared back its ad spend in 2012, a baby born HIV-positive is virus-free two-and-a-half years later, and Boston Children's Hospital is making its own apps.
 

Business briefs: Bayer; Mylan

February 28, 2013

Bayer sees gains despite contraceptives safety hit; Mylan buys Indian injectables firm Agila
 

Business briefs: Endo; Allergan

February 27, 2013

Endo gets a new president, Allergan settles a Botox case
 

Business briefs: Everyday Health; UBM; CompTIA research; JAMA Study

February 26, 2013

Everyday Health's news guru gets a promotion, UBM launches an ad-free pharma space
 

Business briefs: Élan, Teva

February 25, 2013

A buyout offer upsets Elan's post-Tysabri plans, Takeda and Affymax recall Omontys.
 

Business briefs: Roche, Gilead

February 21, 2013

Roche in hot water over UK drinks for docs; HIV/AIDS patient advocates howl over Gilead's Irish tax sheltering patent move
 

Business briefs: Harris Interactive; The Head and Neck Cancer Alliance

February 20, 2013

Harris Interactive hired Matt Knoeck as SVP, healthcare and Sharron Albert as VP, marketing.
 

Business briefs: Sobi and Savient; Novartis; Saatchi & Saatchi Wellness

February 19, 2013

Sobi and Savient Pharmaceuticals inked a co-promote agreement for RA drug Kineret in the US.
 

Business briefs: Celgene

February 14, 2013

Celgene's Pomalyst (pomalidomide), an oral treatment for relapsed and refractory multiple myeloma, was approved by the FDA this week.
 

Business briefs: UCB, Amgen, Novo Nordisk

February 13, 2013

UCB, Amgen dump bone fracture drug amid tighter regs; Tresiba wins approval in Japan; DiabeticConnect tops diabetes sites
 

Business briefs: Amgen and Omnicom Group

February 12, 2013

Amgen said they will continue to spread out their efforts on two different commercial models: biologics and biosimilars.
 

Business briefs: Everyday Health, Novo Nordisk

February 11, 2013

Everyday Health said advertising and sponsorship revenue grew 24% last year and that revenue from their top 20 advertisers grew 28%. Novo Nordisk receives a rejection for drugs, Tresiba and Ryzodeg, from FDA.
 

Business briefs: Takeda, Google, Lundbeck, Elan, Teva

February 07, 2013

Takeda's 1,800 field reps are getting a new tool, Google changes its AdWords program.
 

Business briefs: GlaxoSmithKline, Burson-Marsteller

February 06, 2013

GSK says 2013 will be a springboard for future growth, Burson-Marsteller hands out two new executive titles.
 

Business briefs: Allergan, Amgen, Wiley

February 05, 2013

Allergan's 2013 outlook scores points with at least one analyst, Amgen is laying off 160 staff, and Wiley renews a publishing relationship.
 

Business briefs: Gilead, Shire, The Medicines Co., HHS

February 04, 2013

HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.
 

Business briefs: Novo Nordisk

January 31, 2013

Novo Nordisk promoted a quartet of US execs to SVP and announced sales growth of 18% for 2012.
 

Business briefs: J&J, Genzyme, Roche

January 30, 2013

Johnson & Johnson is said to be shopping its women's division; Genzyme lands a rare disease drug approval; Roche says Avastin had a comeback in 2012; promotions at Ogilvy CommonHealth and McCann Complete Medical
 

Business briefs: Boston Scientific, Eli Lilly, Genzyme

January 29, 2013

Boston Scientific to slash around 1,000 jobs, Lilly exited 2012 7% lighter on sales, Genzyme is seeking a new indication for Lemtrada.
 

Business briefs: Takeda, Stryker

January 28, 2013

Takeda pulls an FDA hat-trick, Stryker buys up a competitor.
 

Business briefs: Biogen Idec, Novartis EuroPharm, Genentech

January 24, 2013

Biogen Idec's long-acting, reduced-dose MS drug hits its trial endpoints, Novartis pulls Ruvise marketing review and Genentech scores a new Avastin indication.
 

Business briefs: Abbott, Sunshine, Allergan and Watson

January 23, 2013

Abbott releases its 2012 numbers, Sen. Grassley demands Sunshine Act action from CMS and Allergan and Watson flex their purchasing power.
 

Business news: Elsevier, FDA

January 22, 2013

Elsevier launches a new title, FDA is holding a public hearing on opioids and chronic pain.
 

Company news: PhRMA, Amgen

January 17, 2013

PhRMA talks up industry pipeline, Amgen's Aranesp fails to hit trial goals.
 

Company news: McCann, Millennium Research Group

January 16, 2013

Internet trends show fondness for online health information, but no need for docs to take on a third job, Millennium says diabetes device market to grow moderately over five years.
 

Company news: Edelman, Pfizer, Publicis, Lippincott

January 15, 2013

Healthcare PR giant Dan Edelman dies; Pfizer says 'no comment' on breakup speculation; Publicis Healthcare snags a new SVP; Lippincott gives nurses a new drug diagnosis tool.
 

Company news: Boehringer Ingelheim, GlaxoSmithKline

January 14, 2013

Boehringer, Horizon Discovery sign collaboration agreement; GSK files for HGS diabetes therapy
 

Company news: Bayer, EMA

January 10, 2013

Bayer scores the first IUD approval in 12 years, EMA raises rates on pharma.
 

Company news: UBM Medica, Bayer

January 09, 2013

Publisher UBM spurs medical competition among psychiatrists, Bayer says it's keeping its diabetes division.
 

Company news: Sanofi, Elsevier

January 08, 2013

Rolaids gets a French twist, and Elsevier packs the second week of the year with two news items.
 

Company news: Boehringer, Eli Lilly, Merck

January 07, 2013

Boehringer Ingelheim doubles down on one diabetes treatment, while parting ways on another; and Merck closes the year as a force in the start-up market.
 

Company news: Biogen Idec, Merck

January 03, 2013

Biogen pulls ALS treatment from its pipeline, Merck resubmits cholesterol combo to FDA
 

Company news: Janssen, Quest, IMS Health

January 02, 2013

Janssen scores an approval for its TB drug; Quest sells off OralDNA; telehealth use poised to rise
 

Company news: Time, Takeda, Amylin, PwC

December 27, 2012

Time Inc. targeted media brand focuses on pharma; Takeda and Amylin call it quits on obesity partnership; PricewaterhouseCoopers builds regulatory intelligence unit
 

Company news: the Orphan Drug Act's surprising savior; Pfizer settles Oregon suit

December 26, 2012

The National Organization for Rare Disorders commended actor Jack Klugman, who died on Monday, for his role in ensuring passage of the Orphan Drug Act of 1983.
 

Company news: Biogen Idec, HHS, Televox

December 20, 2012

Biogen Idec sets aside $10M for ALS research, HHS clears eight exchanges.
 

Company news: Pfizer, Vertex and Poz

December 19, 2012

Pfizer and at least two other pharmas are spreading pink slips instead of cheer
 

Company news: GlaxoSmithKline, Royal Philips

December 18, 2012

GSK, Pfizer and Shionogi's HIV medication to get its day in regulatory court; Philips finds that mobile and health are becoming inseparable.
 

Company news: AstraZeneca, Novartis, Teva

December 17, 2012

AstaZeneca avoids a Lipitor moment, FDA approves Novartis med for Cushing's, and Teva ventures into South Korea. Plus: a closer look at health exchanges
 

Company news: Endo, Lundbeck, Lilly

December 13, 2012

Endo is on the hunt for a new President and CEO, Lundbeck lands a $50 million milestone payment and Lilly scales back a Phase III trial.
 

Company news: Galderma, UCB, GSK

December 12, 2012

Galderma expands its surface area, UCB celebrates RA victories online and GSK pilots a vaccine communications program in Mozambique.
 

Company news: Janssen, Pfizer, BMS and Boehringer Ingelheim

December 11, 2012

Janssen's prostate cancer pill Zytgia got an OK for use in an earlier line of therapy, and drugmakers Pfizer, Bristol-Myers Squibb and Boehringer Ingelheim released new data on blood thinners Eliquis and Pradaxa.
 

Company news: Amgen and DeCODE Genetics; Porter Novelli

December 10, 2012

Amgen is buying deCODE Genetics, an Icelandic firm, for $415 million in cash.
 

Company news: Pfizer, CVS, Challenger Gray

December 06, 2012

Pfizer is diving into the (stem cell) banking business, CVS turns app into vaccine scheduler, Challenger crunches layoff numbers.
 

Company news: AstraZeneca, Alcon, Novo Nordisk

December 05, 2012

AstraZeneca's 7,300 layoffs were not the last word for 2012, Alcon gets hit with an untitled letter from OPDP, and Novo creates an all-diabetic sports team
 

Company news: HBA and Cardinal Health; Bristol-Myers Squibb; Spyglass; Cochrane

December 04, 2012

HBA honors Cardinal Health, BMS adds another drug to the trash heap, Spyglass says nurses don't really like iPads and Cochrane finds texting is a good way to help smokers become quitters.
 

Company news: ComScore, Pfizer, J&J

December 03, 2012

ComScore finds a trend between ads and prescriptions, Pfizer is courting fewer PCPs, Weldon is out as chair in 2013.
 

Company news: Nature Publishing Group, Elsevier, Medicare

November 29, 2012

Nature releases the Antibodypedia's seventh generation, Elsevier adds more board review apps, and how redefining "senior" may not save money in the long run
 

Company news: Edelman, CMS, McKesson

November 28, 2012

Edelman nabs a GolinHarris exec, CMS submits Sunshine regs and McKesson expands its e-coupon reach.
 

Company news: Novo Nordisk

November 27, 2012

Novo Nordisk has launched a hemophilia app; and a report says the Chinese OTC market is going gangbusters
 

Company news: Capgemini, HealthPrize and Warc International

November 26, 2012

The amount of revenue pharma leaves on the table due to non-adherence is much more than previously thought, a new study suggests.
 

Company news: Bristol-Myers Squibb, HHS, Teva

November 21, 2012

EU OKs Eliquis, HHS issues a cancer app challenge and Teva says really big deals are not its focus
 

Company news: FDA, Shire, Bayer

November 20, 2012

A third-party review says FDA employees need more support; Shire launches rare disease research; and Bayer drops Schiff bid
 
  

Web Exclusive

Angelina Jolie's fearless but flawed message

Paul Oestreicher, Ph.D. May 17, 2013

Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful
 

Podcasts

How to engage even the busiest physicians

March 04, 2013

Sponsored by TRUE Health + Wellness. The increasingly demanding schedules of healthcare professionals continue to narrow the window of opportunity for pharma sales teams, and, as a result, marketers are focusing more on non-personal promotion. However, there's a lot more to it than simply bombarding physicians with brand messages, as Anne Stroup, Managing Director at TRUE Health + Wellness, explains to MM&M's James Chase in this special podcast presentation.
 

2013 Hall of Fame Inductees

An entertaining look at the extraordinary lives and careers of the Medical Advertising Hall of Fame's 2013 inductees: Peter Frishauf, Dorothy Philips and David Labson. Clips produced by JUICE Pharma. 

Slideshows

MAHF 2013: Honors Class

A gallery of images from the 2013 Medical Advertising Hall of Fame induction dinner
 
Popular Topics
Acquisition Adherence Advertising Allergy Anaphylaxis Anti-infective App Centers For Disease Control COPD Diabetes Digital Marketing DTC Elan FDA Generic Generic Drugs Lymphoma Marketing & Communications Mobile Oncology Patient Advocacy Pipeline Regulatory Research & Development Roche